Use of daratumumab in therapy of patients with newly diagnosed multiple myeloma complicated by dialysis-dependent kidney failure: literature review and clinical observation

   Multiple myeloma (MM) is a B-cell lymphoproliferative disorder. Its morphological substrate is plasma cells producing monoclonal immunoglobulin. Monoclonal light chains damage nephrons leading to development of acute kidney failure (AKF) which can be diagnosed at MM onset, recurrence, or progression. Dialysis-dependent kidney failure (DDKF) is associated with worse prognosis and decreased overall survival. Currently, the standard of MM therapy complicated by moderate and severe AKF is programs including bortezomib. According to the results of completed trials, achievement of hematological response plays the main role in AKF resolution, therefore, the use of new highly effective regimens of antitumor drug therapy is recommended. Despite the results of large clinical trials showing the effectiveness of daratumumab in therapy of patients with MM, data on its use in patients with newly diagnosed MM complicated by DDKF who are candidates for autologous hematopoietic stem cell transplant are limited. A case of daratumumab therapy (as monotherapy and in combination with lenalidomide, dexamethasone) of a 38-year-old female patient with MM complicated by DDKF and significant adverse events developed during previous short-term treatment with bortezomib is presented. The achieved hematological response (partial remission, absence of minimal residual disease), satisfactory somatic condition, as well as favorable daratumumab safety profile allowed to consider the patient for autologous hematopoietic stem cell transplant and increased the probability of improved renal response with subsequent cancellation of hemodialysis.

1. Walk J.C., Ayati B.P., Holstein S.A. Modeling the efects of multiple myeloma on kidney function. Sci Rep 2019;9(1):1726. DOI: 10.1038/s41598-018-38129-7

2. Gonsalves W.I., Leung N., Rajkumar S.V. et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 2015;5(3):e296. DOI: 10.1038/bcj.2015.20

3. Uttervall K., Duru A.D., Lund J. et al. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS One 2014;9(7):e101819. DOI: 10.1371/journal.pone.0101819

4. Rekhtina I.G., Mendeleeva L.P. Current approaches to treating of patients with multiple myeloma with renal failure: questions and proofs. Terapevticheskiy Arkhiv = Therapeutic archive 2017;89(7): 112–7. (In Russ.). DOI: 10.17116/terarkh2017897112-117

5. Nasr S.H., Valeri A.M., Sethi S. et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis 2012;59(6):786–94. DOI: 10.1053/j.ajkd.2011.12.028

6. Rekhtina I.G., Maryina S.A., Tangieva L.M. et al. The effectiveness of extracorporeal methods in the elimination of light chains in patients with multiple myeloma on programmed hemodialysis. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2013;58(2):29–32. (In Russ.).

7. Hutchison C.A., Bradwell A.R., Cook M. et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4(4):745–54. DOI: 10.2215/CJN.04590908

8. Hutchison C.A., Cockwell P., Stringer S. et al. Early reduction of serumfree light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011;22(6):1129–36. DOI: 10.1681/ASN.2010080857

9. Jagannath S., Barlogie B., Berenson J.R. et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005;103(6):1195–200. DOI: 10.1002/cncr.20888

10. Yadav P., Cook M., Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel) 2016;1(4):241–57. DOI: 10.1159/000442511

11. Dimopoulos M.A., Richardson P., Schlag R. et al. VMP (Bortezomib, Melphalan, and Prednisone) Is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA Study. J Clin Oncol 2009;27(36):6086–93. DOI: 10.1200/JCO.2009.22.2232

12. Ludwig H., Adam Z., Hajek R. et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010;28(30):4635–41. DOI: 10.1200/JCO.2010.28.1238

13. Morabito F., Gentile M., Ciolli S. et al. Safety and efficacy of bortezomibbased regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 2010;84(3):223–8. DOI: 10.1111/j.1600-0609.2009.01385.x

14. Scheid C., Sonneveld P., Schmidt-Wolf I.G. et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 2014;99(1):148–54. DOI: 10.3324/haematol.2013.087585

15. Dimopoulos M.A., Roussou M., Gavriatopoulou M. et al. Bortezomibbased triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol 2016;91(5):499–502. DOI: 10.1002/ajh.24335

16. Semochkin S.V., Zhelnova E.I., Misyurina E.N. et al. Clinical importance of renal recover on outcomes of newly diagnosed multiple myeloma patients with severe and dialysis-dependent kidney failure. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2019;64(3):283–96. (In Russ.). DOI: 10.35754/0234-5730-2019-64-3-283-296

17. Ludwig H., Rauch E., Kuehr T. et al. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica 2015;100(3):385–91. DOI: 10.3324/haematol.2014.115204

18. Dimopoulos M.A., Oriol A., Nahi H. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375(14):1319–31. DOI: 10.1056/NEJMoa1607751

19. Mateos M.V., Dimopoulos M.A., Cavo M. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378(6):518–28. DOI: 10.1056/NEJMoa1714678

20. Facon T., Kumar S., Plesner T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380(22):2104–15. DOI: 10.1056/NEJMoa1817249

21. Voorhees P.M., Kaufman J.L., Laubach J. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136(8):936–45. DOI: 10.1182/blood.2020005288

22. Moreau P., Attal M., Hulin C. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394(10192):29–38. DOI: 10.1016/S0140-6736(19)31240-1

23. Kastritis E., Terpos E., Symeonidis A. et al. Daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results on efficacy and safety of the phase 2 dare study. Blood 2020;136(Suppl 1):48–9.

24. Cejalvo M.J., Legarda M., Abella E. et al. Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study. Br J Haematol 2020;190(5):e289–e92. DOI: 10.1111/bjh.16286

25. Rocchi S., Tacchetti P., Pantani L. et al. Safety and efcacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica 2018;103(6):e277–e8. DOI: 10.3324/haematol.2018.191122

26. Mizuno S., Kitayama C., Mashiko S., Sanada S. Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma. CEN Case Reports 2022;11(2):265–8. DOI: 10.1007/s13730-021-00668-w

27. Lee C.K., Zangari M., Barlogie B. et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004;33(8):823–8. DOI: 10.1038/sj.bmt.1704440

28. Badros A., Barlogie B., Siegel E. et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114(4):822–9. DOI: 10.1046/j.1365-2141.2001.03033.x

29. Antlanger M., Dust T., Reiter T. et al. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer 2018; 18(1):1008. DOI: 10.1186/s12885-018-4926-0

30. El Fakih R., Fox P., Popat U. et al. Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients. Clin Lymphoma Myeloma Leuk 2015;15(8):472–6. DOI: 10.1016/j.clml.2015.03.003

31. Van de Donk N.W., Janmaat M.L., Mutis T. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 2016;270(1):95–112. DOI: 10.1111/imr.12389

32. Michaleas S., Penninga E., Hovgaard D. et al. EMA review of daratumumab (darzalex) for the treatment of adult patients newly diagnosed with multiple myeloma. Oncologist 2020;25(12):1067–74. DOI: 10.1002/onco.13554

33. Jeyaraman P., Bhasin A., Dayal N. et al. Daratumumab in dialysisdependent multiple myeloma. Blood Res 2020;55(1):65–7. DOI: 10.5045/br.2020.55.1.65

34. Dimopoulos M.A., Sonneveld P., Leung N. et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016;34(13):1544–57. DOI: 10.1200/JCO.2015.65.0044